Search results
Satsuma Pharma Shares Nosedives After Disappointing Data From Migraine Study
Benzinga via Yahoo Finance· 1 year agoSatsuma Pharmaceuticals Inc (NASDAQ: STSA) shares are falling after the company reported topline...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 2 months agoXenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript February 29, 2024 Xenon...
KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion
Zacks via Yahoo Finance· 1 month agoKORU Medical Systems, Inc. KRMD has made a strategic move in its pursuit of expanding its footprint...
Talaris (TALS) Down on Patient Death From Renal Transplant Study
Zacks via Yahoo Finance· 2 years agoTalaris Therapeutics (TALS) reports a patient death from its late-stage study evaluating its...
Xenon's Epilepsy Candidate Rapidly Reduces Focal Onset Seizure Frequency
Benzinga via Yahoo Finance· 2 years agoXenon Pharmaceuticals Inc (NASDAQ: XENE) announced new efficacy data supporting the Phase 3...
Satsuma Pharma Shares Are Gaining After Encouraging Update From Migraine Candidate
Benzinga via Yahoo Finance· 2 years agoSatsuma Pharmaceuticals Inc (NASDAQ: STSA) announced favorable safety, tolerability, and efficacy...
This Stock Earns Price Bump, Bullish Pitch On Recent Positive Migraine Drug Data
Benzinga via Yahoo Finance· 2 years agoSatsuma Pharmaceuticals Inc (NASDAQ: STSA) announced positive results from the ASCEND open-label,...
Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA
Zacks via Yahoo Finance· 2 years agoThe FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an...
Court Favors Vanda In Case Against FDA Over Detail Disclosure Of Rejection Of Sleep Disorder Drug
Benzinga via Yahoo Finance· 1 year agoA federal court granted final judgment in favor of Vanda Pharmaceuticals Inc's (NASDAQ: VNDA)...
What's in Store for United Therapeutics' (UTHR) Q2 Earnings?
Zacks via Yahoo Finance· 2 years agoUnited Therapeutics' (UTHR) investor focus is likely to have been on sales figures of Tyvaso,...